Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 8, 2010, Pages 2452-2455

  Fidanze, Steve D ^a   Erickson, Scott A ^a   Wang, Gary T ^a   Mantei, Robert ^a   Clark, Richard F ^a   Sorensen, Bryan K ^a   Bamaung, Nwe Y ^a   Kovar, Peter ^a   Johnson, Eric F ^a   Swinger, Kerren K ^a   Stewart, Kent D ^a   Zhang, Qian ^a   Tucker, Lora A ^a   Pappano, William N ^a   Wilsbacher, Julie L ^a   Wang, Jieyi ^a   Sheppard, George S ^a   Bell, Randy L ^a   Davidsen, Steven K ^a   Hubbard, Robert D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

EGFR; ErbB2; IGF 1R; Imidazo 2,1 b thiazoles; Inhibitor; Kinase

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; IMIDAZO[2,1 B]THIAZOLE DERIVATIVE; SOMATOMEDIN RECEPTOR;

ARTICLE; DRUG ACTIVITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY;

MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 77950033575     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.03.015     Document Type: Article

References (16)

1. Dempke W.C.M., and Heinemann V. Eur. J. Cancer 45 (2009) 1117
2. Quanri J.J.E.F.J., and Esteva F.J. J. Mammary Gland Biology and Neoplasia 13 (2008) 485
3. Goetsch L., Gonzalez A., Leger O., Beck A., Pauwels P.J., Haeuw J.F., and Carvaia N. Int. J. Cancer 113 (2005) 316
4. Wilsbacher J.L., Zhang Q., Tucker L.A., Hubbard R.D., Sheppard G.S., Bamaung N.Y., Fidanze S.D., Wang G.T., Hu X., Davidsen S.K., Bell R.L., and Wang J. J. Biol. Chem. 283 (2008) 23721
5. Hubbard R.D., Bamaung N.Y., Fidanze S.D., Erickson S.A., Palazzo F., Wilsbacher J.L., Zhang Q., Tucker L.A., Hu X., Kovar P., Osterling D.J., Johnson E.F., Bouska J., Wang J., Davidsen S.K., Bell R.L., and Sheppard G.S. Bioorg. Med. Chem. Lett. 19 (2009) 1718
6. Borhani, D. W.; Calderwood, D. J.; Frank, K. E.; Davis, H. M.; Josephsohn, N. S.; Skinner, B. S. WO 2008/063287.
7. A similar scaffold displaying IGF1R activity has also been reported independently of this work:. Emmitte K.A., Wilson B.J., Baum E.W., Emerson H.K., Kuntz K.W., Nailor K.E., Salovich J.M., Smith S.C., Cheung M., Gerding R.M., Stevens K.L., Uehling D.E., Mook Jr. R.A., Moorthy G.S., Dickerson S.H., Hassell A.M., Leesnitzer M.A., Shewchuk L.M., Groy A., Rowand J.L., Anderson K., Atkins C.L., Yang J., Sabbatini P., and Kumar R. Bioorg. Med. Chem. Lett. 19 (2009) 1004
8. Lackey K.E. Curr. Top. Med. Chem. 6 (2006) 435
9. Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R., Abdel-Meguid S., Adams J.L., and Goldsmith E.J. Structure 6 (1998) 1117
10. Boehm J.C., and Adams J.L. Expert Opin. Ther. Patents 10 (2000) 25
11. Garcia-Echeverria, C. WO 2005/068452.
12. Lansing T.J., McConnell R.T., Duckett D.R., Spehar G.M., Knick V.B., Hassler D.F., Noro N., and Furuta M. Mol. Cancer Ther. 6 (2007) 450
13. The kinase activities of disclosed compounds were assayed by a homogeneous time-resolved fluorescence assay as previously described. The inhibition of intracellular phosphorylation by selected compounds was assayed using ELISA as previously described:. Hubbard R.D., Bamaung N.Y., Palazzo F., Zhang Q., Kovar P., Osterling D.J., Hu X., Wilsbacher J.L., Johnson E.F., Bouska J., Wand J., Bell R.L., Davidsen S.K., and Sheppard G.S. Bioorg. Med. Chem. Lett. 17 (2007) 5406
14. Stevens K.L., Jung D.K., Alberti M.J., Badiang J.G., Peckham G.E., Veal J.M., Cheung M., Harris P.A., Chamberlain S.D., and Peel M.R. Org. Lett. 7 (2005) 4753
15. The refined crystallographic coordinates have been deposited in the Protein Data Bank (www.rcsb.org) with entry code 3LZB.
16. Compound 26 has been tested against a panel of 56 kinases for selectivity. Data can be found in Supplementary data.